Clinical Trial Update: Premedication to Reduce Amivantamab Associated Infusion Related Reactions [Phase 2]

View source ↗

Summary

Phase 2 trial update examining premedication to reduce infusion-related reactions with amivantamab in non-small cell lung cancer; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Rybrevant (amivantamab-vmjw) (amivantamab-vmjw)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-10-20